Skip to main content

Baodong Sun, PhD

Associate Professor of Pediatrics
Campus mail: 905 Lasalle Street, GSRB1 Room 4044, Durham, NC 27710
Phone: (919) 681-8933
Email address: baodong.sun@duke.edu

My overall research interests are finding effective treatment for human glycogen storage diseases (GSDs) and other inherited metabolic disorders. My current research focuses on identification of novel therapeutic targets and development of effective therapies for GSD II (Pompe disease), GSD III (Cori disease), and GSD IV (Andersen disease) using cellular and animal disease models. The main therapeutic approaches we are using in our pre-clinical studies include protein/enzyme therapy, AAV-mediated gene therapy, and substrate reduction therapy with small molecule drugs.

Education and Training

  • Ph.D., China Medical University (China), 1995

Publications

Korlimarla, Aditi, Jeong-A Lim, Priya S. Kishnani, and Baodong Sun. “An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond..” Ann Transl Med 7, no. 13 (July 2019). https://doi.org/10.21037/atm.2019.04.49.

Full Text

Brooks, Elizabeth D., Haiqing Yi, Baodong Sun, Jeong-A Lim, Carine A. Halaby, Lani K. Clinton, Alisha M. Mavis, et al. “COMPARATIVE LIVER PATHOLOGY IN GLYCOGEN STORAGE DISEASE TYPE IIIA.” In Molecular Genetics and Metabolism, 127:256–57. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2019.

Scholars@Duke

Kishnani, Priya S., Baodong Sun, and Dwight D. Koeberl. “Gene therapy for glycogen storage diseases..” Hum Mol Genet, June 22, 2019. https://doi.org/10.1093/hmg/ddz133.

Full Text

Lim, Jeong-A, Su Jin Choi, Fengqin Gao, Priya Kishnani, and Baodong Sun. “Correction of Glycogen Storage Disease Type III with an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme.” In Molecular Therapy, 27:17–17. CELL PRESS, 2019.

Scholars@Duke

Lim, Jeong-A, Haiqing Yi, Fengqin Gao, Nina Raben, Priya S. Kishnani, and Baodong Sun. “Intravenous Injection of an AAV-PHP.B Vector Encoding Human Acid α-Glucosidase Rescues Both Muscle and CNS Defects in Murine Pompe Disease..” Mol Ther Methods Clin Dev 12 (March 15, 2019): 233–45. https://doi.org/10.1016/j.omtm.2019.01.006.

Full Text

Brooks, Elizabeth D., Haiqing Yi, Baodong Sun, Jeong-A Lim, Carine A. Halaby, Lani K. Clinton, Alisha M. Mavis, et al. “COMPARATIVE LIVER PATHOLOGY IN GLYCOGEN STORAGE DISEASE TYPE IIIA.” In Molecular Genetics and Metabolism, 126:291–291. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2019.

Scholars@Duke

Korlimarla, A., S. Austin, B. Sun, and P. Kishnani. “Hepatic Manifestations in Glycogen Storage Disease Type III.” Current Pathobiology Reports 6, no. 4 (December 1, 2018): 233–40. https://doi.org/10.1007/s40139-018-0182-x.

Full Text

Lim, Jeong-A, Baodong Sun, Rosa Puertollano, and Nina Raben. “Therapeutic Benefit of Autophagy Modulation in Pompe Disease..” Mol Ther 26, no. 7 (July 5, 2018): 1783–96. https://doi.org/10.1016/j.ymthe.2018.04.025.

Full Text

Lim, Jeong-A, Haiqing Yi, Fengqin Gao, Priya Kishinani, and Baodong Sun. “A Single Intravenous Injection of an AAV-PHP. B Vector Encoding Human Acid alpha-Glucosidase Corrects Both Muscle and Brain Defects in Murine Pompe Disease.” In Molecular Therapy, 26:382–83. CELL PRESS, 2018.

Scholars@Duke

Lim, Han-Hyuk, Haiqing Yi, Takashi K. Kishimoto, Fengqin Gao, Baodong Sun, and Priya S. Kishnani. “A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease..” Mol Genet Metab Rep 13 (December 2017): 18–22. https://doi.org/10.1016/j.ymgmr.2017.03.005.

Full Text

Pages